Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 13Neoplasms 7Brain Neoplasms 6Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Tongue Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Relapsed Pediatric Solid Tumor 1Recurrence 1Precancerous Conditions 1Optic Nerve Glioma 1Non-squamous Non-small Cell Lung Cancer 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Diseases 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Familial ependymoma 1

Interventions

camrelizumab 2apatinib 2sintilimab 1Vinorelbine 1Pemetrexed 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Respiratory Tract Diseases × Erlotinib Hydrochloride × Clear all
NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
144 enrolled
Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡